Gilead Sciences

Linda-Gail Bekker has played a significant role in #HIV prevention efforts globally, and has championed the representation of underrepresented communities in research programs. Hear more from her on the importance of community in our collective work to end the epidemic. #IAS2025

Women are leading efforts to help end #HIV by driving research, raising awareness and advocating for better health for all. Hear more from #IAS2025 on the importance of their perspectives in innovation.

At #IAS2025, we invited advocates to share the impact of community involvement in the #HIV landscape. Hear how, together, we’re helping shape the future of research and taking steps to end the epidemic.

Nearly 40% of people living with #HIV reported starting treatment more than 30 days post-diagnosis. To help bridge this gap, it’s imperative to heighten awareness of the benefits of rapid treatment initiation. Learn more about our research at #IAS2025. gilead.inc/4nVbbsU%E2%8...

At Gilead, our focus is on turning scientific innovation into real-world impact. Our recent agreement with The Global Fund will help expand access to our #HIV prevention medicine once approved in high-incidence, resource-limited countries. #IAS2025

Inclusion in #HIV research leads to better, more equitable outcomes. Yvette Raphael and Moupali Das share how they helped shape Gilead’s prevention trials by prioritizing the voices of young women and adolescent girls. #IAS2025

The results of our new global survey gather insights from people living with HIV – a diverse representation of multiple historically underrepresented communities. This spotlights our commitment to putting people at the center. gilead.inc/3TC9DpY #IAS2025

We’re proud to bring our people-first mission to #IAS2025. We’re driving innovation to help end the #HIV epidemic for everyone, everywhere.